CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

even if its main focus remains on therapeutic areas where it currently has an established presence, Chief Executive Vas Narasimhan said in an interview with The Wall Street Journal.

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...

While CEO-designate Vas Narasimhan kept tightlipped on this point in the press conference, an answer came a few hours later, with a deal with groundbreaking gene therapy company Spark Therapeutics ...

said chief executive Vas Narasimhan. The event comes just over a year after Novartis completed the dismantling of its diversified life sciences model with the spinout of generic and biosimilar ...

CEO Vas Narasimhan said in an interview. Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter ...